Humacyte, Inc. (HUMA)
NASDAQ: HUMA · IEX Real-Time Price · USD
3.100
+0.030 (0.98%)
At close: Mar 27, 2024, 4:00 PM
3.090
-0.010 (-0.32%)
Pre-market: Mar 28, 2024, 7:00 AM EDT

Humacyte Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Revenue
1.571.261.496.19
Revenue Growth (YoY)
23.91%-15.29%-75.90%-
Gross Profit
1.571.261.496.19
Selling, General & Admin
22.8821.1312.0116.28
Research & Development
63.2661.3454.0875.6
Operating Expenses
86.1482.4766.0991.88
Operating Income
-84.58-81.21-64.6-85.69
Interest Expense / Income
6.24.352.22.3
Other Expense / Income
-78.81-59.08-0.28-2.57
Pretax Income
-11.97-26.48-66.52-85.42
Net Income
-11.97-26.48-66.52-85.42
Shares Outstanding (Basic)
10340620
Shares Outstanding (Diluted)
10340620
Shares Change
157.82%593.25%-71.34%-
EPS (Basic)
-0.12-0.66-11.54-4.25
EPS (Diluted)
-0.12-0.66-11.54-4.25
Free Cash Flow
-72.18-81.41-55.84-79.91
Free Cash Flow Per Share
-0.70-2.04-9.68-3.97
Gross Margin
100.00%100.00%100.00%100.00%
Operating Margin
-5404.35%-6429.77%-4332.66%-1385.02%
Profit Margin
-764.54%-2096.36%-4461.70%-1380.67%
Free Cash Flow Margin
-4611.95%-6445.76%-3744.87%-1291.61%
EBITDA
2.49-13.85-55.89-76.31
EBITDA Margin
159.11%-1096.28%-3748.49%-1233.44%
Depreciation & Amortization
8.268.288.436.81
EBIT
-5.77-22.13-64.32-83.12
EBIT Margin
-368.37%-1752.10%-4314.02%-1343.53%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).